Iovance Biotherapeutics (Nasdaq: IOVA) is a commercial stage immuno-oncology company aspiring to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Our lead candidate, AMTAGVI® (lifileucel), was granted accelerated approval for metastatic melanoma by the U.S. FDA and became the first approved one-time cell therapy for a solid tumor cancer. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.
